Stocks › BMY
BRISTOL MYERS SQUIBB CO
BMY·NYSE·
United States·USD
$58.80
+0.46 (+0.79%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BMY
BRISTOL MYERS SQUIBB CO · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BMYS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BMY by members of U.S. Congress · 322 on record · 17 in the last 12 months
Whale Activity
Position changes in BMY reported for 2026-09-30 by 2698 institutional filers
- Increased1007
- New196
- Held328
- Decreased937
- Closed126
- No prior filing104
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 173.7M | $10.84B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 133.7M | $8.34B | increased |
| STATE STREET CORP | 103.3M | $6.45B | increased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 72.5M | $4.52B | increased |
| JPMORGAN CHASE & CO | 60.2M | $3.79B | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 50.6M | $3.15B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 47.1M | $2.94B | increased |
| BANK OF AMERICA CORP /DE/ | 40.3M | $2.51B | increased |
| MORGAN STANLEY | 28.4M | $1.77B | decreased |
| FMR LLC | 28.3M | $1.77B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 27.5M | $1.72B | decreased |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 25.7M | $1.60B | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BMY insiders, by quarter · Form 4
Recent Insider Transactions
3,751 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Haller Julia ADirector · Director | Sale | −3,800 | $63.31 | $241K | Nov 5, 2026 | Form 4 ↗ |
| Massacesi CristianEVP,Chief Med Offr,Head of Dev | Sale | −6,249 | $64.57 | $403K | Sep 9, 2026 | Form 4 ↗ |
| Short Bartie WendyEVP, Corporate Affairs | Tax withholding | −633 | $66.92 | $42K | Sep 1, 2026 | Form 4 ↗ |
| Short Bartie WendyEVP, Corporate Affairs | Option exercise | +1,236 | $66.92 | $83K | Sep 1, 2026 | Form 4 ↗ |
| Holzer Phil MSVP and Controller | Sale | −500 | $67.50 | $34K | Aug 25, 2026 | Form 4 ↗ |
| Massacesi CristianEVP,Chief Med Offr,Head of Dev | Tax withholding | −26.2K | $65.31 | $1.7M | Aug 1, 2026 | Form 4 ↗ |
| Massacesi CristianEVP,Chief Med Offr,Head of Dev | Option exercise | +51.2K | $0.00 | $0 | Aug 1, 2026 | Form 4 ↗ |
| Gallman CariEVP, General Counsel | Tax withholding | −543 | $65.31 | $35K | Aug 1, 2026 | Form 4 ↗ |
| Gallman CariEVP, General Counsel | Option exercise | +1,061 | $0.00 | $0 | Aug 1, 2026 | Form 4 ↗ |
| Haller Julia ADirector | Option exercise | +20.5K | $53.76 | $1.1M | Jun 15, 2026 | Form 4 ↗ |
| Short Bartie WendyEVP, Corporate Affairs | Tax withholding | −3,876 | $54.72 | $212K | Jun 3, 2026 | Form 4 ↗ |
| Short Bartie WendyEVP, Corporate Affairs | Option exercise | +8,040 | $0.00 | $0 | Jun 3, 2026 | Form 4 ↗ |
| Lenkowsky AdamEVP, Chief Commercial Officer | Tax withholding | −599 | $58.22 | $35K | May 1, 2026 | Form 4 ↗ |
| Lenkowsky AdamEVP, Chief Commercial Officer | Other | −203 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
| Lenkowsky AdamEVP, Chief Commercial Officer | Option exercise | +1,373 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
| Shanahan KarinEVP, Chief Supply Chain & Ops | Tax withholding | −1,692 | $61.73 | $104K | Apr 1, 2026 | Form 4 ↗ |
| Shanahan KarinEVP, Chief Supply Chain & Ops | Option exercise | +3,307 | $0.00 | $0 | Apr 1, 2026 | Form 4 ↗ |
| Elkins David VEVP, Chief Financial Officer | Sale | −4,481 | $62.05 | $278K | Apr 1, 2026 | Form 4 ↗ |
| Elkins David VEVP, Chief Financial Officer | Sale | −25.5K | $61.60 | $1.6M | Apr 1, 2026 | Form 4 ↗ |
| Short Bartie WendyEVP, Corporate Affairs | Tax withholding | −828 | $60.13 | $50K | Mar 10, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BMY · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 64.8M | $3.74B | 0.16% | Jun 30, 2026 |
| Schwab U.S. Dividend Equity ETF SCHWAB STRATEGIC TRUST | 55.8M | $3.73B | 3.32% | Aug 31, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 52.9M | $3.05B | 0.18% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 26.5M | $1.77B | 0.21% | Aug 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 28.1M | $1.62B | 0.18% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 24.7M | $1.43B | 0.18% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 19.4M | $1.12B | 0.44% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF SELECT SECTOR SPDR TRUST | 14.4M | $831.3M | 2.05% | Jun 30, 2026 |
| VANGUARD PRIMECAP FUND VANGUARD CHESTER FUNDS | 14.3M | $823.6M | 0.86% | Jun 30, 2026 |
| VANGUARD INSTITUTIONAL INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 11.1M | $638.8M | 0.18% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BMY's shares (CUSIP 110122108), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 102.5M shares5.0%
Aug 7, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 153.1M shares7.5%
Apr 29, 2026 · ↗ - The Vanguard GroupSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Mar 26, 2026 · ↗ - JPMORGAN CHASE & CO.SCHEDULE 13G · passive (13G) · 104.7M shares5.1%
Apr 25, 2025 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 143.6M shares7.1%
Apr 17, 2025 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming bristol myers squibb as client
- FEDERAL STREET STRATEGIES, LLCBRISTOL MYERS SQUIBB COMPANY · 2026 Q3 · HCR$50K
Filing ↗ - ALEXANDER J. BECKLES, L.L.C.BRISTOL MYERS SQUIBB · 2026 Q3$30K
Filing ↗ - MARSHALL & POPP, LLCBRISTOL-MYERS SQUIBB COMPANY · 2026 Q3 · PHA$60K
Filing ↗ - MILLER STRATEGIES, LLCBRISTOL-MYERS SQUIBB COMPANY · 2026 Q3 · HCR, MMM—
Filing ↗ - CAPITOL COUNSEL LLCBRISTOL-MYERS SQUIBB · 2026 Q3 · HCR, MED, MMM$60K
Filing ↗
Government Contracts
Federal awards to bristol myers squibb · USAspending
$5.7MAwarded · 29 contracts on record
- Department of Veterans AffairsPOMALYST 2 MG, 3MG, 4 MG$94K
Feb 11, 2026 · ↗ - Department of Veterans AffairsREVLIMID DIFFERENT DOSES$0
Feb 2, 2026 · ↗ - Department of Veterans AffairsIBERDOMIDE HCL 1MG$22K
Nov 2, 2026 · ↗ - Department of Veterans AffairsCAMZYOS AND POMALYST$1.0M
Oct 1, 2026 · ↗ - Department of Veterans AffairsMAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST)$371K
Jan 29, 2026 · ↗ - Department of Veterans AffairsCAMZYOS, POMALYST, AND REVLIMID$72K
Jan 20, 2026 · ↗ - Department of Veterans AffairsREVLIMID 10MG CAP$0
Jan 30, 2026 · ↗ - Department of Veterans AffairsEMERGENCY BREYANZI$0
Jun 30, 2026 · ↗
U.S. Patents
Recent USPTO applications naming BRISTOL MYERS SQUIBB CO
No USPTO patent applications found for BRISTOL MYERS SQUIBB CO.
Annual Financials
From BMY's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Net income | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B |
| Diluted EPS | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 |
| Operating cash flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B |
| Cash and equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B |
| Total assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B |
| Total liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B |
| Shareholders' equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B |
As BRISTOL MYERS SQUIBB CO tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitMar 1, 1999
- 2-for-1Stock splitMar 3, 1997
- 2-for-1Stock splitJun 10, 1987
- 2-for-1Stock splitMay 27, 1983
- 2-for-1Stock splitMay 31, 1977
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureOct 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureJul 30, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureApr 30, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureFeb 5, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJan 12, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsNov 18, 2025
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsNov 10, 2025
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsNov 3, 2025
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureOct 30, 2025
EDGAR ↗
About BRISTOL MYERS SQUIBB CO
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersPRINCETON, NJ
IncorporatedDE
SEC CIK0000014272 ↗









